{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE268nnn/GSE268123/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE268123"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Sequencing analysis of CD4 positive CAR T cells pre treated with dexamethasone","description":"In this research, we conducted a preliminary comparison of the in vitro anti-tumor effectiveness and phenotype of CD4+ and CD8+ CAR T cells. Our findings indicate that following multiple rounds of tumor cell stimulation, CD4+ CAR T cells demonstrated robust proliferation capabilities with reduced apoptosis rates, while also maintaining their effector phenotype. To further optimize the functionality of CD4+ CAR T cells, we implemented a low-dose decitabine pretreatment strategy for CAR T cells (referred to as dCAR T) during the CAR T cell preparation process. After three rounds of in vitro tumor cell stimulation, dCAR T cells exhibit sustained anti-tumor efficacy and proliferation capacity. Analysis of bulk RNA sequencing data validates the enhanced effector phenotype and proliferation potential of dCAR T cells relative to conventional CAR T cells. These findings indicate that pretreatment with decitabine may modulate the transcriptional profile of CAR T cells.","dates":{"publication":"2026/05/31"},"accession":"GSE268123","cross_references":{"GSM":["GSM8286065","GSM8286066","GSM8286063","GSM8286074","GSM8286064","GSM8286072","GSM8286061","GSM8286073","GSM8286062","GSM8286070","GSM8286071","GSM8286069","GSM8286067","GSM8286068"],"GPL":["18573","24676"],"GSE":["268123"],"taxon":["Homo sapiens"]}}